國家衛生研究院 NHRI:Item 3990099045/11963
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12145/12927 (94%)
造访人次 : 914782      在线人数 : 1398
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/11963


    题名: Long-term clinical outcomes of IMRT with simultaneous integrated boost for breast cancer
    作者: Lee, H;Huang, M
    贡献者: NHRI Graduate Student Program
    摘要: Purpose or Objective: To report the long-term survival outcomes and late toxicities resulted from intensity modulated radiotherapy (IMRT) with simultaneous integrated boost (SIB) for breast cancer patients after breast conserving surgery (BCS). Material and Methods: The study included 216 patients with pathologically proven breast cancer who underwent BCS between 2010 and 2013. The median age was 52 years (Range: 21 to 81). All patients received IMRT-SIB to 2 dose levels simultaneously. They received 50.4 Gy at 1.8 Gy per fraction to the whole breast and 60.2 Gy at 2.15 Gy per fraction to the tumor bed by integral boost. The fractionation scheme was biologically equivalent to the sequential boost-technique comprising 25 fractions of 2 Gy to the whole breast PTV followed by a boost irradiation in 6 fractions, using an alpha/beta ratio of 4 Gy for tumor response, based on the linear-quadratic cell survival model. Dermatological toxicities were assessed and documented in agreement with the Common Toxicity Criteria Adverse Events version 3 (CTCAE v.3.0). Cox regression model and Kaplan-Meier curves were calculated, and the log-rank test was used to evaluate the differences of overall (OS) and disease free (DFS) survival rates between two different modalities of radiotherapy. Results : Among 216 patients, 174 received post-operative radiotherapy with Rapid-Arc and 42 patients had Tomotherapy after BCS. All patients tolerated IMRT-SIB without any interruption. The median follow-up was 6.4 years. Four patients (1.85%) in the entire cohort developed late skin complication after IMRT-SIB. For the entire cohort, the 5-year and 7-year OS rates were 94.4% and 93.1% respectively. The 5-year and 7-year DFS rates were 94.9% and 94.0 % respectively. Conclusion: There exists no statistically significant difference in the rates of locoregional recurrence and overall survival when comparing RapidArc with Tomotherapy. IMRT-SIB was well tolerated with small late skin complication and good survival rates.
    日期: 2019-04
    關聯: Radiotherapy and Oncology. 2019 Apr;133(Suppl. 1):S713.
    Link to: http://dx.doi.org/10.1016/s0167-8140(19)31722-0
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0167-8140&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000468315603262
    显示于类别:[其他] 會議論文/會議摘要

    文件中的档案:

    档案 描述 大小格式浏览次数
    ISI000468315603262.pdf213KbAdobe PDF234检视/开启


    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈